Analysts expect Cempra, Inc. (NASDAQ:CEMP) to announce $2.48 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Cempra’s earnings. The lowest sales estimate is $880,000.00 and the highest is $4.55 million. Cempra posted sales of $3.97 million in the same quarter last year, which would indicate a negative year over year growth rate of 37.5%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.
On average, analysts expect that Cempra will report full-year sales of $2.48 million for the current financial year, with estimates ranging from $7.50 million to $15.33 million. For the next fiscal year, analysts anticipate that the business will report sales of $13.81 million per share, with estimates ranging from $5.00 million to $25.49 million. Zacks’ sales averages are an average based on a survey of research firms that cover Cempra.
Cempra (NASDAQ:CEMP) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The business had revenue of $0.86 million for the quarter, compared to analyst estimates of $3.58 million. During the same period in the previous year, the company earned ($0.51) earnings per share. The company’s revenue for the quarter was down 74.9% compared to the same quarter last year.
A number of research analysts have weighed in on CEMP shares. Zacks Investment Research raised shares of Cempra from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Jefferies Group LLC reissued a “neutral” rating on shares of Cempra in a research report on Thursday, October 26th. Roth Capital lowered shares of Cempra from a “buy” rating to a “neutral” rating and cut their target price for the stock from $8.00 to $4.00 in a research report on Thursday, August 10th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $4.00 target price on shares of Cempra in a research report on Thursday, August 10th. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Cempra has an average rating of “Hold” and an average price target of $8.50.
Shares of Cempra (CEMP) traded up 3.37% during mid-day trading on Friday, hitting $2.30. The stock had a trading volume of 1,282,480 shares. Cempra has a one year low of $2.05 and a one year high of $18.90. The firm’s 50 day moving average price is $3.01 and its 200-day moving average price is $3.61. The company’s market cap is $120.77 million.
A number of large investors have recently bought and sold shares of CEMP. Voya Investment Management LLC raised its position in Cempra by 34.1% in the second quarter. Voya Investment Management LLC now owns 23,006 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 5,848 shares in the last quarter. Janney Montgomery Scott LLC raised its position in Cempra by 35.6% in the second quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 6,800 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new position in Cempra in the first quarter worth about $140,000. LMR Partners LLP acquired a new position in Cempra in the second quarter worth about $149,000. Finally, Ameriprise Financial Inc. acquired a new position in Cempra in the second quarter worth about $164,000. 49.39% of the stock is owned by hedge funds and other institutional investors.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Cempra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cempra Inc. and related companies.